If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
302
results.
Updated on
24/04/2026 [07:12:00]
Results 966 to 302 of 302
Absstract of: CN121868254A
本发明涉及一种基于溶酶体的纳米载药颗粒及其应用，属于生物医药技术领域。本发明将溶酶体膜作为仿生膜来源包覆于药物纳米颗粒表面，在保持溶酶体膜结构稳定性的同时最大程度保留其天然存在的水解酶活性，使该纳米载药颗粒在体内递送过程中能够对肿瘤组织细胞外基质进行原位降解，从而有效削弱肿瘤组织的物理屏障，显著增强纳米药物在肿瘤组织中的渗透、分布及细胞摄取能力，并在此基础上改善免疫细胞进入肿瘤组织的条件，最终提高肿瘤治疗效果。
Absstract of: CN120899945A
The invention discloses a tumor targeted diagnosis and treatment integrated system based on organic-inorganic dynamic assembly and a preparation method thereof, the system takes an aminated mesoporous nano-material as a carrier to load a chemotherapeutic drug and a photothermal agent, and realizes alpha v beta 3 integrin targeting through RGD peptide modification. And furthermore, sodium alginate (Alg-NB) grafted with a pH/NIR dual-response o-nitrobenzyl benzene light trigger (NB) is utilized, and through Schiff base reaction and calcium ion crosslinking dynamic coating, an intelligent nano diagnosis and treatment platform is formed. According to the invention, a'dynamic gating 'release mechanism is created for the first time, and time-space controllable drug release is realized. By integrating a photo-thermal/photodynamic, chemotherapy and active targeting triple synergistic treatment mode, an efficient anti-tumor effect is achieved. In addition, the system achieves the diagnosis and treatment integrated function in a breakthrough mode, has the near-infrared fluorescence imaging and thermal imaging guiding capacity, and provides support for precise treatment in an operation. The invention provides a new idea for a new generation of organic-inorganic dynamically assembled targeted integrated diagnosis and treatment system.
Absstract of: CN121868250A
本发明提供一种负载雷帕霉素的工程化细菌纳米囊泡、制备方法及其应用，属于生物医药与纳米制剂领域，其为中空的球状形貌，具有磷脂双分子层结构，磷脂双分子层间嵌入脂溶性雷帕霉素，表面涂覆一层磷酸钙矿化壳，形成AbNV/Rapa@CaP。通过提取细菌膜成分并与雷帕霉素共同孵育，经挤出形成均匀的纳米囊泡AbNV/Rapa，再通过离心和矿化步骤，为其包裹上一层pH响应性的钙磷矿化涂层，最终得到完整的AbNV/Rapa@CaP。应用于制备抗肿瘤药物。本发明能够从肿瘤相关巨噬细胞复极化及抗衰老的角度促进巨噬细胞吞噬肿瘤细胞；制备方法设计合理，制备工艺简单，具有广阔的应用前景，同时也为相应给药系统的设计和发展打下基础。
Absstract of: CN121868248A
本发明公开一种光活性共轭分子的药物递送系统及其制备方法和应用，涉及光功能复合材料和生物医药技术领域。所述药物递送系统以红细胞为载体，所述红细胞的细胞内负载有光活性共轭分子和抗肿瘤药物。本发明提供的制备方法简单易行，有效整合共轭分子光敏性能与红细胞的氧气载体功能，具有良好的生物相容性和稳定性。光照后，借助红细胞的氧气运输能力，共轭分子能够在肿瘤缺氧微环境下有效地产生活性氧，同时，产生的活性氧能够破坏红细胞，实现负载药物的按需释放，达到增强光疗疗效、按需药物释放以及成像的多功能集成，实现光动力治疗与化疗的协同抗肿瘤作用。因此在生物医学领域具有很好的实用价值。
Absstract of: CN121868245A
本发明公开了一种纳米酶制剂的制备方法及其产品和应用。所述纳米酶制剂的合成方法包括以下步骤：将跨膜蛋白溶液和含有一种或多种纳米酶的溶液混合，制备纳米酶制剂。本发明利用纳米酶可以靶向疾病部位，在疾病部位该纳米酶一方面清除活性氧和活性氮物种；另一方面该纳米酶能够与疾病部位的细胞因子结合，抑制细胞因子对疾病的促进作用，达到防治结肠炎与结肠炎相关结肠癌疾病的效果。本发明所开发的纳米酶不仅能够减轻疾病氧化应激，还可以减少细胞因子的促炎和促肿瘤的作用，可以有效治疗由结肠炎恶化引起的结肠炎相关结肠癌。
Absstract of: CN121868505A
本发明提供一种丹参酮IIA纳米复合物、脑靶向药物系统、药物制剂及应用。本发明的丹参酮IIA纳米复合物包括（1）丹参酮IIA，以及（2）包载所述丹参酮IIA的纳米载体，所述纳米载体包括壳聚糖衍生物，所述壳聚糖衍生物与D‑α‑生育酚琥珀酸酯连接；其中，所述纳米载体与丹参酮IIA之间通过交联剂连接。本发明的脑靶向药物系统包括RVG29和所述丹参酮IIA纳米复合物。本发明的丹参酮IIA纳米复合物、脑靶向药物系统可用于制备预防或治疗神经退行性疾病的药物。
Absstract of: CN121868464A
本发明提供了一种基于Th1/Th2免疫动态平衡的联合疫苗及其制备方法和应用，通过在肿瘤发生早期采用白介素12（IL12）与抗原（如卵清蛋白OVA）mRNA的皮下递送，以激活机体特异性抗原识别与T细胞免疫反应；在免疫应答进入功能衰退阶段时，再通过白介素4（IL4）mRNA的瘤内递送，以调节肿瘤微环境、维持T细胞代谢活性并延缓T细胞耗竭。本发明通过不同免疫因子的空间（皮下/瘤内）与时间（早期/中期）分离递送，实现了“启动—稳态维持”式的免疫程式化调控，显著增强了抗原特异性CTL反应及持久性抗肿瘤效应，克服了各自单独使用的免疫偏倚问题。
Absstract of: CN121873391A
本发明涉及一种疏水短链淀粉纳米颗粒及其制备方法与应用，属于天然产物技术领域。本发明提供了疏水短链淀粉纳米颗粒的制备方法，包括以下步骤：将经湿热处理的淀粉与α‑淀粉酶混合，在30‑40℃、180‑220rpm下反应1‑5h，灭酶处理后得到酶解后的淀粉；对酶解后的淀粉进行糊化处理，得到糊浆，将糊浆与普鲁兰酶在55‑60℃下反应4‑8h，灭酶处理后得到短链淀粉；利用反溶剂沉淀法将上述短链淀粉制备为短链淀粉纳米颗粒；利用柠檬酸酯化交联短链淀粉纳米颗粒，得到疏水短链淀粉纳米颗粒。本发明通过将经湿热处理的淀粉进行两步酶解制备为短链淀粉，通过反溶剂沉淀法与柠檬酸酯化交联制备得到疏水性高的短链淀粉纳米颗粒。
Absstract of: CN121868251A
一种负载姜黄素的MMP响应型蜂毒肽纳米菌膜囊泡、其制备方法及其应用，属于药物制剂技术领域。制备方法为：首先制备包载姜黄素的脂质体；随后将携带蜂毒肽重组质粒的工程菌进行培养扩增，经去除细胞壁后提取细胞膜，并通过超声处理及膜挤压获得蜂毒肽细胞膜纳米囊泡；再将所述姜黄素脂质体与所述细胞膜纳米囊泡通过超声挤出方式进行融合，得到融合囊泡；最后对融合囊泡进行表面磷酸钙矿化处理，获得负载姜黄素的MMP响应型蜂毒肽纳米菌膜囊泡。本发明制备的纳米菌膜囊泡可用于制备抗肿瘤药物，通过引入磷酸钙涂层，提高纳米粒子的生物相容性和体内稳定性；通过蜂毒肽与姜黄素的联合递送，有利于增强抗肿瘤作用效果，从而抑制肿瘤细胞的生长和增殖。
Absstract of: CN121868246A
本发明公开了一种益生菌的纳米封装方法及所得纳米封装益生菌，属于微生物制剂技术领域。本发明提供的纳米封装方法，包括如下步骤：提供益生菌菌液，使其与三价铁离子溶液混合，以使三价铁离子吸附于益生菌表面；使吸附有三价铁离子的益生菌菌液与富含羧基的阴离子多糖溶液混合，通过离子交联在益生菌表面形成纳米凝胶层；将包覆有纳米凝胶层的益生菌菌液与多酚化合物溶液混合，通过配位络合形成金属‑多酚网络，得到纳米封装益生菌。本发明通过在益生菌表面依次构建纳米凝胶层与金属‑多酚网络，利用二者的协同保护机制，成功实现了对益生菌的高效单细胞封装，使其在胃酸环境中的存活率与在肠道中的定殖能力均得到显著提升。
Absstract of: CN121868253A
本发明涉及一种FZD1主动靶向纳米粒的制备方法，包括以下步骤：S1、利用DSPE‑PEG2000‑COOH和多肽UM206合成DSPE‑PEG2000‑UM206;S2、利用聚乳酸‑羟基乙酸共聚物以及DSPE‑PEG2000‑UM206合成FZD1主动靶向纳米粒。由于采用了上述技术方案，本发明FZD1主动靶向纳米粒的制备方法所制备的FZD1主动靶向纳米粒能够促进骨肉瘤细胞对PLGA纳米粒的吞噬，骨肉瘤干样细胞（后续描述中简称为OCSCs）对本发明FZD1主动靶向纳米粒的制备方法所制备的FZD1主动靶向纳米粒的吞噬效率高。
Absstract of: CN121868244A
本发明属于药剂领域，公开了一种可治疗糖尿病的纳米药物制剂及其制备方法。该制备方法包括：将果糖‑1,6‑二磷酸锶、五氧化二钒、麦角硫因通过水热反应，制得锶‑钒酸有机框架纳米颗粒；将锶‑钒酸有机框架纳米颗粒与多巴胺、聚赖氨酸共混在碱性条件下实现聚多巴胺的包埋，形成聚赖氨酸‑聚多巴胺共包埋有机框架纳米颗粒，即为治疗糖尿病的纳米药物制剂。该纳米药物制剂能够释放氧钒配合物，麦角硫因，提高血锶浓度及其半衰期，从而控制血糖，改善糖尿病症状，并改善糖尿病并发骨质疏松、动脉硬化等症。
Absstract of: CN121868455A
本发明提供了一种降糖、细胞修复、抗氧化及增强免疫力的复合植物多肽组合物及其制备方法与应用，属于生物技术领域。本发明提供的组合物，包括由小米蛋白肽、大豆分离蛋白肽、乳清蛋白肽和沙棘蛋白肽组成的蛋白肽、由奇亚籽粉和魔芋粉组成的膳食纤维、由乳双歧杆菌BB‑12和鼠李糖乳杆菌LGG组成的益生菌复合物和低聚果糖、由苦瓜肽、青钱柳提取物、玉米须提取物、桑叶提取物、葛根提取物、黄精多糖提取物、辣木叶提取物和水蛭粉组成的提取物混合物、维生素矿物质混合物和其余功能成分。本发明提供的组合物通过搭配多种蛋白质、膳食纤维、益生菌益生元、植物提取物、维生素矿物质及其余功能成分等，最终实现了能够有效从多靶点、多途径协同改善糖尿病及肾病病情的目的。
Absstract of: CN121873133A
本发明提供了一种钌左氧氟沙星配合物及其制备方法与应用，属于有机物合成技术领域。钌左氧氟沙星配合物Ru (II)‑1具有式Ⅰ所示结构：式Ⅰ。本发明提供的钌左氧氟沙星配合物可被红光光照激活，实现抗生素的光响应性释放，从而发挥光激活抗菌的功能。之后通过该配合物包裹半乳糖聚合物纳米胶束颗粒PGal NPs制备成纳米胶束颗粒Ru (II)‑1@ PGal NPs，实现了对耐药细菌的精准靶向抑制。
Absstract of: CN121868252A
本发明提供了脂肪干细胞人工纳米囊泡在制备用于促进血小板生成的药物中的用途。本发明还提供了一种装载有地榆单体DMAG的脂肪干细胞人工纳米囊泡，其通过提取脂肪干细胞的细胞膜，并利用细胞膜天然的磷脂双分子层结构对DMAG进行包载，以形成纳米规格的囊泡结构。该人工纳米囊泡不仅继承了脂肪干细胞的良好生物相容性，可有效降低机体免疫排斥反应，保护DMAG免受体内酶解等降解作用；还可以在体内形成保护性递送体系，从而减少DMAG在体内被快速代谢与清除，延长其在体内的有效释放时间。人工纳米囊泡显著增加外周血血小板数量，缩短出血时间，同时降低免疫原性。
Absstract of: CN121868475A
本发明公开了一种纳米铟佐剂及其制备方法和应用，属于纳米医药技术领域。本发明将铟的三氯化物与PVP溶液混合，并与没食子酸溶液进行金属离子螯合，得均一和稳定的纳米铟佐剂。然后通过将抗原卵白蛋白与纳米铟佐剂形成纳米铟佐剂疫苗，同时激活了体液免疫和细胞免疫，增强了抗原的递呈能力和免疫原性，满足临床对抗肿瘤疫苗的需求。
Absstract of: CN121872965A
本公开提供了一种脂质化合物和脂质纳米颗粒组合物，所述脂质化合物具有如式I所示结构。本公开提供的脂质纳米颗粒粒径分布较好，包封率高，且递送效果优异，能够满足体内递送的需求。
Absstract of: CN121868568A
本发明涉及生物医药技术领域，尤其涉及一种可控释放外泌体水凝胶及其制备方法和应用。利用本发明提供的可控释放外泌体水凝胶的制备方法制备而成的可控释放外泌体水凝胶，相较于现有的外泌体递送系统，具备以下几方面显著优势：一、能够实现精准的时空调控；二、能够提升外泌体的生物活性；三、能够适应创伤微环境；四、集外泌体治疗、光热抗菌、止血、促血管生成等功能于一体；五、生物相容性优异，细胞存活率高；六、动物实验结果表明，本发明提供的可控释放外泌体水凝胶有助于促进伤口的愈合；在全层皮肤缺损与深二度烧伤模型中，能够加速上皮化与胶原沉积，进而减少疤痕的形成。因此，有望应用制备创面修复产品。
Absstract of: CN121868265A
本发明属于生物医药技术领域，具体提供了一种ALO@F127‑MOF纳米复合物及其制备方法和应用。所述ALO@F127‑MOF纳米复合物以具有普朗尼克F‑127涂层的UiO‑66‑NH2 MOF作为纳米载体，苦豆碱负载于所述纳米载体上。将该纳米复合物用于ALI的治疗，有效改善了中药苦豆碱的溶解度、稳定性和生物利用度，实现了苦豆碱的持续释放、ROS中和以及有效靶向的协同效应。基于雾化的递送方法确保了更好的氧合、更低的全身毒性和更优的肺部沉积。本发明为无创急性肺损伤治疗提供了新的治疗方法。
Absstract of: CN121868249A
本发明公开了一种通过鼻腔途径实现大脑靶向的脂质纳米颗粒及其递送方法与应用。所述脂质纳米颗粒其原料包括肽基可离子化脂质、辅助磷脂、甾族脂质、聚乙二醇脂质；其中，肽基可电离脂质的结构式如式I所示，肽基可离子化脂质占总脂质的摩尔百分比为45‑65%；辅助磷脂占总脂质的摩尔百分比为10‑20%，甾族脂质占总脂质的摩尔百分比为30‑50%，聚乙二醇脂质占总脂质的摩尔百分比为1‑5%。将核酸分子包裹在所述脂质纳米颗粒中，形成包载核酸的脂质纳米颗粒。本发明确立了一种非侵入性、高效的脑靶向mRNA递送平台，为拓展mRNA疗法在神经领域的应用奠定了坚实基础。
Absstract of: CN121868247A
一种调控mRNA转染的糖苷甾醇成分脂质纳米粒及其制备方法和应用属于药物制剂制备技术领域，纳米粒由DLin‑MC3‑DMA、DOPE、不同糖苷或甾醇及DSPE‑PEG‑GSH组成。不同糖苷或甾醇包括：苦杏仁苷Amy、β‑谷甾醇、豆甾醇Sti、人参皂苷Rg1、红景天苷Sal。豆甾醇可以提升LNP在脾脏的富集，人参皂苷可以调节免疫的作用增强抗肿瘤免疫效果，制备方法简单，所需设备均为常规设备，可实现大规模生产，因此具有良好的工业化应用价值和市场前景。
Absstract of: CN121868225A
本发明提供了一种载药明胶纳米凝胶、仿生纳米凝胶及其制备方法和联合用药物与用途，属于生物医药技术领域。本发明将全反式维甲酸与吡非尼酮和明胶反应形成载药明胶纳米凝胶，协同抑制胰腺星状细胞活化与阻断促纤维化信号通路，实现对胰腺癌纤维化微环境的逆转；同时，将载药明胶纳米凝胶包覆于活化的胰腺星状细胞膜构建仿生纳米凝胶，使其具备主动靶向性，显著提升药物的递送效率与治疗效果；并将载药明胶纳米凝胶、仿生纳米凝胶和化疗药物联合用于治疗胰腺癌，具有显著抗肿瘤效果，且仿生纳米凝胶与吉西他滨的联合治疗具有协同增效的抗肿瘤作用。本发明凝胶实现了对胰腺癌致密纤维化微环境的有效调控，为胰腺癌的治疗提供了一种可行的新策略。
Absstract of: CN121868480A
本发明涉及生物医药技术领域，具体涉及了一种用于清除胞内细菌的纳米药物及其制备方法和用途。该纳米药物由中空介孔纳米颗粒、负载于其中的抗菌药物、接枝于颗粒表面的代谢激活分子以及包覆于最外层的经灭活细菌预刺激的免疫细胞融合膜组成。通过代谢激活、靶向杀菌、免疫唤醒的协同作用机制，有效解决了现有技术难以克服的胞内细菌代谢休眠、药物靶向递送效率低及宿主免疫抑制微环境的技术难题。实验表明，该纳米药物能特异性靶向感染部位，逆转细菌代谢休眠状态，同步实现高效杀菌与免疫激活，在对金黄色葡萄球菌等引起的胞内感染治疗中表现出卓越的清除效果，并能有效建立持久免疫记忆，显著降低感染复发率。
Absstract of: WO2025032322A1
A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.
Absstract of: WO2025034764A1
Ionizable lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Absstract of: WO2025010290A1
The present disclosure relates to cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of using and delivering the described lipids and lipid-containing particles.
Absstract of: CN121872927A
本公开提供了一种脂质化合物和脂质纳米颗粒组合物，所述脂质化合物具有如式I所示结构。本公开提供的脂质纳米颗粒粒径分布较好，包封率高，且递送效果优异，能够满足体内递送的需求。
Absstract of: WO2026078444A1
The disclosure relates to the development of a nano-encapsulated extract of Mitragyna speciosa, commonly known as kratom, specifically designed for use in beverages, dietary supplements and natural health products. This extract is standardized to contain a precise concentration of mitragynine, the primary active alkaloid in kratom, ensuring consistent potency and efficacy in enhancing energy, alertness, and alleviating minor pain, such as delayed inset muscle soreness, associated with physical exertion. The disclosed technology outlines an extraction and encapsulation process that not only maximizes the yield of mitragynine but also ensures the removal of undesirable compounds and the encapsulation provides improved bioavailability, thereby enhancing the safety profile of the final product. The standardized extract may be easily incorporated into various beverage formulations, dietary supplements and natural health products, providing a reliable and effective herbal supplement option.
Absstract of: US20260102452A1
The invention introduces a nanoemulsion-based nanocream formulated from green ingredients, designed to improve performance, stability, and sustainability. The nanoemulsion is developed using the low-energy Phase Inversion Temperature (PIT) method, which leverages the system's internal chemical energy to minimize external energy input, protect heat-sensitive compounds, and lower production costs. During PIT, polyethoxylated surfactants, hydrophilic at lower temperatures, become lipophilic when heated as their polyoxyethylene groups dehydrate, triggering phase inversion from oil-in-water (O/W) to water-in-oil (W/O). Rapid cooling with continuous stirring reverts to the O/W phase, causing turbulence and generating a stable nanoemulsion with nano-sized droplets of high uniformity. This nanoemulsion replaces water in the cream's aqueous phase, forming a nanocream that enhances bioactive delivery to the skin. The cream's thick, highly viscous oily base minimizes the risk of coalescence and further improves the overall stability of the nano-sized droplets containing bioactive oils.
Absstract of: WO2026077099A1
Provided are a protein/polyester/lipid-nucleic acid delivery system for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The system is prepared from an aqueous phase comprising a nucleic acid and a protein, and an organic phase comprising a hydrophobic degradable aliphatic polyester and a derivative thereof, and an ionizable lipid and/or a cationic lipid material. The preparation method comprises mixing an aqueous phase and an organic phase by using a single emulsification technology or a high-pressure homogenization technology to obtain a protein nanoassembly for targeted nucleic acid delivery. The protein is albumin or a single-chain antibody-albumin fusion protein. The stable protein nanoassembly is applied to a targeted nucleic acid delivery platform, and is applied to a nucleic acid treatment drug for tumors, autoimmune diseases, or inflammatory diseases.
Absstract of: WO2026078579A1
The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.
Absstract of: DE102024129442A1
Die Erfindung betrifft ein Konjugat umfassend mindestens ein Polymer und mindestens einen Antikörper oder mindestens ein Antikörperfragment, wobei das Polymer ausgewählt ist aus Poly(dimethyl acrylamid) (PDMA), Poly(oligoethylen glykol methacrylat) (POEGMA), Poly(2-hydroxypropyl methacrylamid) (PHPMA), Poly(vinylpyrrolidon) (PVP), Poly(2-methylsulfinyl)ethyl acrylat (PMSEA), Poly(6-O-methacyloyl-D-galactopyranose) (PMAGP), Acrylsäure (PAA), Poly(carboxybetain acrylat) (PCBA), Poly(vinylphosphonsäure) (PVPA), Poly(vinylbenzoesäure) (PVBzA), Poly(propylacrylsäure) (PPAA), Poly(styrolsulfonsäure) (PSS), Polyglycerol (PG) und Polyäpfelsäure (PMA) und das mindestens eine Antikörperfragment vorzugsweise mindestens einen Einzeldomänenantikörper (Nanobody) umfasst. Die Erfindung betrifft ferner die medizinische Verwendung des Konjugats, sein Herstellungsverfahren und Kits für dessen Anwendung.
Absstract of: US20260102509A1
A nanoparticle compound comprising buckminsterfullerene C60 bonded to ester functional groups of pyruvic, citric, and hyaluronic acids, with oxygen-bridged components selected from vanadium, gallium, and bismuth is provided. At least one component enables quantum-mechanical spin-wave activation. Ultrasonic irradiation activates the compound, inducing electrical induction for tissue healing and cell growth. The compound integrates with native and 3D-printed tissues, enhancing their properties through interpenetrating networks. It exhibits anti-inflammatory, antioxidant, and antibacterial effects, reinforces connective tissue, and modulates stem cell growth. The compound treats arthritis, enhances gut health and barrier function, supports bone health, improves voice quality, counters cancer cell proliferation, and mitigates osteoporosis. The gallium component creates an alkaline environment for calcium deposition, while vanadium enhances chondrogenic differentiation. Administration methods include topical application, oral ingestion, injection, and infusion through bandages or sutures. The compound serves as an adjuvant for analgesics, enhancing their delivery and efficacy.
Absstract of: WO2026080471A2
The disclosure relates generally to tRNA-based effector molecules and conjugates thereof comprising moieties (e g., carbohydrates, lipids, peptides, small molecules, oligonucleotides) and methods, compositions, and uses relating thereto.
Absstract of: WO2026080839A1
Immunoreactive peptides that can be used to detect or generate an immune response against Ehrlichia bacteria are provided. The immunoreactive peptides may be included in a diagnostic kit or pharmaceutical composition or vaccine composition. Methods of diagnosing or detecting exposure to E. canis in a mammalian subject, such as a dog, are also provided.
Absstract of: WO2026080826A1
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Absstract of: WO2026080622A1
Provided herein are compounds, such as compounds of Formula (I), and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of therapeutic cargo (e.g., polynucleotides, such as mRNA). In particular, the compounds described herein may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to a cell, a tissue, or a subject.
Absstract of: WO2026079308A1
The present invention provides: lipid nanoparticles that include a nucleic acid, cKK-E12, and DOPC, the molar ratio of the cKK-E12 to the DOPC content being 0.2–15.0; and a production method for the lipid nanoparticles that includes a step for preparing a lipid solution that includes cKK-E12, DOPC, a sterol, and a PEG lipid, a step for preparing a nucleic acid solution that includes a nucleic acid, and a step for mixing the lipid solution and the nucleic acid solution.
Absstract of: WO2026078426A1
A targeted nanocarrier for delivering drugs to targeted cells. The targeted nanocarrier may comprise a nano-colloid suspension of poly(phenyllactic-co-kojic-co-gluconic acid) (poly(PLKGA)), the nano colloid suspension of poly(PLKGA) comprising: a dispersed phase comprising a plurality of nanoparticles of poly(PLKGA); and a continuous phase comprising a medium of the nano-colloid suspension of poly(PLKGA).
Absstract of: WO2026077978A1
The present invention relates to nanoparticles capable of crossing biological barriers. In particular, it refers to lipid nanoparticles configured to cross the blood-brain barrier, target skeletal tissues and effectively penetrate the skin barrier. The invention also encompasses compositions and applications thereof.
Absstract of: WO2025052296A1
The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls. The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil® second generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts WO2022129966. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, micro RNA, circular DNA, small biologically active molecules) into the cells.
Absstract of: AU2024342596A1
The present invention relates to a material for local drug delivery, and use thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.
Absstract of: AU2024336703A1
The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.
Absstract of: WO2026077307A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Absstract of: AU2026202277A1
Abstract Disclosed therein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.
Absstract of: US20260102362A1
Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.
Absstract of: AU2025271161A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors. ov o v
Absstract of: US20260102349A1
Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.
Absstract of: US20260102345A1
The present invention refers to polyoxyalkylene based compounds and their manufacturing method as well as compositions containing at least one polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Absstract of: US20260102503A1
Generally, the present disclosure is directed to compositions and methods of using the same. In some embodiments, a composition described herein comprises a nanoparticle, a plurality of nanofibers disposed on an exterior surface of the nanoparticle, and a payload disposed within an interior of the nanoparticle. The nanoparticle has an average size in three dimensions, and the plurality of nanofibers has an average length in a long dimension. In some cases, a ratio of the average size of the nanoparticle to the average length of the nanofibers is between 2 and 250.
Absstract of: US20260102347A1
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making said lipids. The lipids may have the structure of Formula A as defined herein. Formula A
Absstract of: US20260102357A1
The present disclosure relates to a sulfur-containing ionizable lipid or a pharmaceutically acceptable salt thereof that incorporates a dithioacetal or dithioketal moiety in one or more of its lipophilic chains. Further provided is a delivery vehicle, such as a lipid nanoparticle, comprising the ionizable lipid for the delivery of cargo, such as nucleic acid.
Absstract of: US20260102468A1
According to various aspects of this disclosure, the present disclosure relates to combination therapies, methods, and kits comprising MARCO blocking agents and anti-cancer agents for improvement of nanoformulated drug delivery. Further, wherein a method of treating a tumor or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination therapy comprising a first agent and a second agent, wherein the first agent is capable of blocking the inter-action between a Macrophage Receptor with Collagenous Structure (MARCO) and a nanoparticle, and the second agent comprises an anti-cancer agent or an anti-tumor agent, and wherein at least the second agent is in the form of a nanoformulation, is disclosed.
Absstract of: US20260104425A1
The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translation; CFT) or inside a cell (cell-based translation; CBT) and analyzed using LC-MS/MS. The method provides advantages such as speed and convenience over traditional immunoassay-based methods of detecting translated proteins. Translation using CBT may be necessary in certain formulations of the mRNA, such as when the mRNA or a mixture of mRNAs is encapsulated inside a lipid nanoparticle.
Absstract of: US20260102346A1
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition including a therapeutic agent and/or a prophylactic agent such as an RNA can be used for delivering the therapeutic agent and/or the prophylactic agent to a mammalian cell or organ, so as to, for example, regulate polypeptide, protein, or gene expression.
Absstract of: US20260102427A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO2 nanoparticles and/or aggregates of HfO2 nanoparticles, a composition comprising said nanoparticles and/or aggregates of nanoparticles, and their use in the treatment of NP.
Absstract of: US20260103501A1
Human SIRPa fusion proteins having an enhanced affinity to CD47 via increased binding valency. The human SIR-Pa fusion proteins described herein may form tetramer, hexamer, octamers, etc. These fusion proteins may be configured to form heterodimers with other fusion proteins, including C-C chemokine receptor type 4 (CCR4) binding fusion proteins.
Absstract of: WO2026077273A1
Provided are a composition containing a lipid nanoparticle (LNP) and an mRNA, and use thereof in the treatment of Gaucher disease. The composition contains an LNP and an mRNA, and the mRNA is encapsulated in the LNP or associated with the LNP, wherein the mRNA contains a nucleotide sequence encoding GBA1. The composition can effectively increase the expression and activity of β-glucocerebrosidase (β-GCase) in the serum and multiple target organs of a subject, and reduce the level of glucosylsphingosine (Lyso-GL1) therein. In addition, the composition possesses a relatively long half-life and has application prospects in the treatment of Gaucher disease.
Absstract of: AU2024382503A1
A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.
Absstract of: AU2024356988A1
Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.
Absstract of: AU2024359608A1
The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
Absstract of: AU2026202273A1
Abstract Compositions and articles comprising diamond particles, such as nanodiamond-based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).
Absstract of: US20260102500A1
The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and/or at least one lipid and/or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.
Absstract of: US20260102348A1
An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, X represents —NR1— or —O—, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.
Absstract of: US20260103715A1
The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
Absstract of: EP4725504A1
A polymeric prodrug nanoparticle for the targeted accumulation and activation in tumor tissue, consisting of the following monomers:a) at least one platinum(IV) complex andb) at least one sonosensitizer, andc) a compound having a hydrophilic group providing this hydrophilic group at each terminal end of the prodrug nanoparticle, wherein a), b) and c) are each covalently bonded to one another by means of a linker and a) and b) are arranged stochastically distributed within the polymeric prodrug nanoparticle can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. Upon irradiation of the polymeric prodrug nanoparticle with ultrasound, the platinum(IV) prodrug is activated in the tumor region, resulting in the release of cytotoxic platinum and killing of tumor cells.
Absstract of: KR102716110B1
The present invention relates to a microfluidic device for producing lipid nanoparticles capable of delivering nucleic acids, and a method for producing lipid nanoparticles using the same. By using the microfluidic device, lipid nanoparticles having a desired size may be prepared by adjusting the molar ratio between the compositions and the reynolds number.
Absstract of: WO2024256457A1
The present invention provides, in part, tricene and citric acid-based cationic lipids with aromatic head groups of Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: WO2024253582A1
There is provided a nanoparticle composition comprising a compound represented by general formula (1) or ionized form thereof, wherein R1, R2, and R4 to R8 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene, and R9 and R10 are each independently a hydrophobic tail or contains at least one of the groups defined above for R4 to R8; a therapeutic, prophylactic, and/or biological agent that is encapsulated by the compound of general formula (1) to form nanoparticles; and a cryoprotectant. There is also provided a method of preparing said nanoparticle composition.
Absstract of: EP4725938A1
The present invention relates to an ionizable lipid compound, a lipid carrier comprising same and the use thereof. Provided in the present invention are a series of compounds as represented by formula (1), a lipid carrier comprising same as an ionizable lipid, a nucleic acid lipid nanoparticle composition and a preparation thereof. A lipid nanoparticle formed from the ionizable lipid can deliver a nucleic acid molecule into the body, so that the transfer rate of a nucleic acid molecule is increased, and the treatment effect of a nucleic acid drug is improved.
Absstract of: WO2024252406A1
Present disclosure describes a lipid polymer hybrid nanoparticle and a method to synthesize such nanoparticles or such nanoparticle-containing compositions. The nanoparticles are made of biodegradable polymer based micellar core surrounded by lipid-based shell, wherein majority of a pharmaceutical agent is present on the inner periphery of such nanoparticles due to physical adherence with the lipid molecules. Only a minor amount of the pharmaceutical agent is encapsulated in the micellar core. Hence, the lipid-based shell becomes a primary excipient part of the nanoparticle and the biodegradable polymer containing core becomes a secondary excipient part of the nanoparticle.
Absstract of: GB2644439A
The invention provides a peptide or a salt or amide thereof, for use as a cell delivery agent, comprising, or consisting of: (Xaa1)a-(Xaa2)b-LYRLFRKS-(Xaa3)c-(Xaa4)d-(Xaa4)e-NLKPFERHARAC, wherein: a, b, and c can be either 0 or 1; d and e are 1; Xaa1-2 represent Ala, Val or Gly; and Xaa3-5 represent His or Trp. An exemplary sequence, AALYRLFRKSWHNLKPERHARAC, when combined with mRNA, forms 103 nm nanoparticles with a charge of 19 mV and polydispersity index of 0.06, and can transfect NCTC-929 cells with an efficiency of up to 81%. The particles are also shown to encapsulate miRNA and plasmid DNA with an encapsulation efficiency up to 95%. Also claimed is the first medical use of the peptide in gene therapy, and second medical use of the peptide in the treatment of prophylaxis, infection, cancer and wounds.
Absstract of: FR3149503A1
La particule submicronique est sensiblement sphérique comprenant un cœur huileux renfermant l’actif peptidique et une enveloppe de cire solide à température ambiante. La particule est stabilisée par une couche extérieure d’un tensio-actif non-ionique à haut HLB. L’invention propose un procédé pour obtenir une suspension aqueuse desdites particules présentant un taux d’encapsulation satisfaisant et une stabilité à long terme améliorée, pour une utilisation notamment dans l’industrie des cosmétiques. Des combinaisons de peptides sont possibles intégrées à l’intérieur des particules et adsorbés à l’extérieur. Fig. 1
Absstract of: EP4725977A1
Disclosed in the present invention are an efficient cationic polyester and the use thereof. The cationic polyester of the present invention is a hyperbranched polymer formed by means of polymerizing three monomers of monomer P, monomer S and monomer M, or two monomers of monomer P and monomer S, with monomer T. The hyperbranched polymer has an end group modified with group E, and the group E has a relative concentration of 0.48-0.75 to group E of a hyperbranched polymer with complete end-group modification. Monomer P is cyclic lactone. Monomer S is an organic acid with an end group containing two or more carboxyl. Monomer M is a compound containing two hydroxyl and one secondary amine or tertiary amine. Monomer T is a compound containing at least three hydroxyl. The end-group modifying compound E which provides group E modification is a compound containing at least one primary amine, secondary amine or tertiary amine group. The cationic polyester of the present invention only has a part of the end groups modified with group E, has higher nucleic acid transfection efficiency when being used for nucleic acid drug delivery, has low cytotoxicity, and can be used in clinical practice.
Absstract of: WO2024251979A1
The present invention is comprised within the fields of molecular biology and biotechnology. It specifically relates to polypeptides for the generation of Backpacked-antibody (B-ab) molecules for a variety of uses, in particular, for the specific delivery of drugs to tumor cells.
Absstract of: EP4726038A1
This application relates to an engineered RNA molecule, a DNA molecule encoding the engineered RNA molecule, and use of the engineered RNA molecule. The engineered RNA molecule comprises a Poly(A) tail sequence containing an miRNA binding site. The Poly(A) tail enables the accurate expression of a target gene in an organ, a tissue and/or a cell.
Absstract of: GB2644423A
The invention relates to sterile veterinary formulations for treating or preventing mastitis in cattle. The formulations comprise a suspension of Derivatised Microparticles, optionally in combination with Microparticles, in an amount of 5 percent to 60% w/v. The Derivatised Microparticles and Microparticles are biodegradable and are formed from an organic polycationic polymer and a saturated or unsaturated fatty dicarboxylic acid. Suitable polymers may include organic polymeric amines, quaternary ammonium compounds, polypeptides and carbohydrates, with preferred antimicrobial polymers such as nisin, ε‑polylysine or chitosan. In preferred embodiments, the microparticles are formed from sebacic acid and ε‑polylysine and the fatty dicarboxylic acid to polymer molar ratio is around 1:1. The suspension may comprise 20 % to 50 % microparticles, preferably around 30 %, in a veterinary acceptable carrier such as water, mineral oil, liquid paraffin or white soft paraffin. The microparticles may be present as a mixture, with the ratio of Derivatised Microparticles to Microparticles ranging from 90:10 to 10:90. The formulation may be administered during the dry period of the cow and provides an effective method for treating or preventing mastitis. The invention further includes mixtures of Derivatised Microparticles and Microparticles and veterinary formulations containing such mixtures.
Absstract of: WO2024253741A1
Compositions are provided that include a lipid nanoparticle (LNP);a self-replicating RNA encoding a gene of interest loaded within the LNP; and an inhibitory nucleic acid, such as a small interfering RNA (siRNA) targeting IFN-α/β receptor l(Ifharl) gene loaded within the LNP, and use of the compositions for generating an immune response.
Absstract of: CN121846047A
本发明公开了CD177靶向膜修饰脂质体在制备预防和/或治疗系统性红斑狼疮的药物中的应用。所述CD177靶向膜修饰脂质体，其结构分为三层，包括：负载PADI4抑制剂的脂质体、在所述脂质体的表面偶联CD177靶向肽形成的靶向识别层、以及最外层包覆天然中性粒细胞膜形成的仿生功能层。在咪喹莫特（IMQ）诱导的狼疮模型中，所述药物治疗显示出强大的疾病缓解能力：1）改善全身表型：显著缩小狼疮小鼠肿大的脾脏和淋巴结。2）修复肾脏功能：显著缓解肾小球肾炎，减少肾小球内炎性细胞浸润、IgG及补体C3沉积。3）显著降低血清中促炎细胞因子水平及狼疮标志物抗dsDNA抗体的滴度。
Absstract of: US12016865B2
0001 A method for treating Candida Auris in blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treat C. Auris in the blood.
Absstract of: CN121846046A
本发明公开了一种双肽修饰仿生纳米囊泡及其制备方法与应用，属于生物医药领域。所述双肽修饰仿生纳米囊泡包括由PLGA形成的纳米颗粒，所述纳米颗粒负载有具有神经保护或神经修复作用的药物；所述纳米颗粒表面包覆有表达RVG肽和T7肽的巨噬细胞膜。所述双肽修饰仿生纳米囊泡通过工程化巨噬细胞膜同时呈现T7肽与RVG肽，利用T7肽高亲和力结合血脑屏障转铁蛋白受体实现高效入脑，借助RVG肽特异性识别脑内星形胶质细胞，实现了对病灶区域目标细胞的精准识别与递送，同时保留了巨噬细胞膜天然的炎症趋向性与免疫逃逸能力，解决了传统递药系统靶向精度低、跨屏障与脑内分布难以协同的难题。
Absstract of: CN121846049A
本发明公开了一种肉桂醛纳米颗粒制备方法及其应用，制备方法以肉桂醛为功效成分，玉米醇溶蛋白为载体，酪蛋白酸钠为稳定剂，果胶为稳定剂和粘合剂，制备获得所述肉桂醛纳米颗粒。经试验验证，本发明制备的肉桂醛纳米颗粒能显著提高肉桂醛的稳定性，同时增强其对于金黄色葡萄球菌的抗菌活性，为肉桂醛的开发利用提供了更多选择。
Absstract of: CN121846300A
本发明公开了一种莲源多糖靶向纳米载药系统及其应用，由活性成分和包裹所述活性成分的载体材料组成；所述活性成分为莲藕多糖LSP‑1，所述LSP‑1是从莲藕中提取纯化的均一多糖，分子量为3.2×10⁴Da，其单糖组成为葡萄糖、半乳糖和阿拉伯糖，摩尔比为5.2:2.8:1.0；所述载体材料为两亲性聚合物，以聚β‑氨基酯为主链，主链中引入二硫键，聚合物末端修饰有穿膜肽TAT和聚乙二醇；本发明首次提出并验证了“汇聚式协同”免疫调控新机制。本发明观察到的“汇聚式协同”效应是特定于“LSP‑1”与“本发明的PBAE基响应型载体”这一组合的，二者在机制上存在特定的生化信号通路交互，并非任何免疫调节剂与任何纳米载体的简单叠加所能实现。
Absstract of: CN121846273A
本发明公开了一种纳米载体Ir‑Mn‑CMP NPs的制备及其生物医学应用。所述纳米载体Ir‑Mn‑CMP NPs通过利用声敏剂铱（III）配合物【Iridium(III) complex，Ir(III)】、锰（Mn）和环状GMP‑AMP（cGAMP）的组合，联合声动力治疗与STING（stimulator of interferon genes）通路激活免疫治疗，提升抗肿瘤治疗效果。此设计不仅能够增强声敏剂的稳定性和水溶性，还能够提高Mn的肿瘤靶向性和生物利用度，同时实现声动力治疗和STING通路免疫激活的双重治疗效果。
Absstract of: CN121849857A
本发明提供了一种基于聚乙烯吡咯烷酮修饰的硒纳米粒子的制备方法，包括以下步骤：S1、还原反应：在惰性气体保护下，将硒源与硼氢化钠在水溶液中于室温下进行还原反应，生成硒氢化钠中间体；S2、稳定化反应：向步骤S1所得的反应体系中加入聚乙烯吡咯烷酮水溶液，继续在惰性气体保护下进行稳定化反应，使聚乙烯吡咯烷酮修饰在生成的硒纳米粒子表面；S3、纯化与收集：将步骤S2所得的反应液进行纯化，去除小分子杂质，然后进行冻干，即得到基于聚乙烯吡咯烷酮修饰的硒纳米粒子固体粉末。本发明提供的基于聚乙烯吡咯烷酮修饰的硒纳米粒子的制备方法，具有原料更安全、工艺更简洁、产物更纯净等优点。
Absstract of: CN121846175A
本发明公开了一种黄芪甲苷协同型组合物及其制备方法与应用，黄芪甲苷协同型组合物其原料按重量份数计，包括如下组分：黄芪甲苷8‑16份、金银花提取物20‑40份、左旋肉碱10‑20份、酵母硒0.1‑0.5份、甘草酸二铵3‑8份、牛磺酸5‑15份、连翘提取物8‑20份、维生素E2‑7份、羟丙基‑β‑环糊精12‑32份、麦芽糊精2‑10.5份、阿拉伯胶1‑7份、乳糖10‑20份、葡萄糖酸锌1‑3份、硬脂酸镁2‑5份、维生素C 1‑3份、黄原胶1‑5份和卵磷脂1‑3份。该组合物在在制备兽药或兽用食品添加剂中具有广泛的应用前景。
Absstract of: CN121846277A
本发明属于纳米马达技术领域，具体涉及一种MXene@Au光热纳米马达及其制备方法和应用。本发明提供的MXene@Au复合纳米马达，包括改性单层MXene纳米片以及负载于改性单层MXene纳米片表面的活性组分；所述活性组分为牛血清白蛋白包覆的金纳米簇；所述改性单层MXene纳米片经阳离子表面活性剂改性得到；所述负载通过静电吸附作用实现。本发明提供的MXene@Au纳米马达在光照下产生非对称热梯度，驱动纳米马达在溶液中实现自推进运动，可显著增强在复杂生物介质中的扩散效率与Aβ靶向富集能力，进而实现对Aβ蛋白聚集体的高效识别与光热降解。
Absstract of: CN121846048A
本申请涉及纳米医药载体技术领域，尤其涉及一种基于酰化多糖和小檗碱的复合载药纳米粒及制备方法和应用。所述制备方法包括：使用碱性催化剂和酸酐将天然多糖进行酰化改性，得到酰化天然多糖；其中，所述酰化改性的方式包括乙酰化改性或者丙酰化改性；在有机溶剂中，将小檗碱和酰化天然多糖进行包封处理，得到基于酰化多糖和小檗碱的复合载药纳米粒。该制备方法通过对天然多糖进行酰化改性，调整天然多糖的疏水性，实现小檗碱包封率的显著提升。一方面，该复合载药纳米粒可以显著提升小檗碱的生物利用度，并延长小檗碱在体内的作用时间，另一方面，该复合载药纳米粒可以促进金黄色葡萄球菌感染的伤口的修复愈合，降低金黄色葡萄球菌的耐药性。
Absstract of: CN121852306A
本发明属于中药技术领域，公开了枳实来源的细胞外囊泡样纳米颗粒，其特征在于，所述枳实来源的细胞外囊泡样纳米颗粒通过将枳实进行破碎、过滤、离心、重悬的步骤制备得到，平均粒径为60~120 nm，该细胞外囊泡样纳米颗粒包载柚皮苷、新橙皮苷、柚皮素和橙皮苷中的至少一种。本发明的枳实来源的细胞外囊泡样纳米颗粒制备方法简单，具有肝脏靶向性和良好的稳定性，可用于制备预防和/或治疗肝损伤、抑郁症与乳腺癌的药物。
Absstract of: CN121846257A
本发明公开了一种细粒棘球蚴及脑多头蚴双联mRNA疫苗及其制备方法，所述双联mRNA疫苗包括同时表达Eg95重组蛋白和TM16重组蛋白的mRNA，以及包封所述mRNA的LNP，记为Eg95‑TM16 mRNA‑LNP。本发明将Eg95和TM16重组蛋白与Eg95‑TM16 mRNA‑LNP分别免疫小鼠及绵羊，结果表明，Eg95和TM16混合重组蛋白和Eg95‑TM16 mRNA‑LNP可通过激活CD8+T淋巴细胞免疫应答，从而发挥抗寄生虫感染的保护作用；同时，Eg95‑TM16 mRNA‑LNP在羊体内表现出良好的稳定性和一致的免疫原性，主要引起以IgG抗体水平升高为主的体液免疫应答，抗体动力学与小鼠数据相似。Eg95‑TM16 mRNA‑LNP免疫组增强的细胞因子诱导优于重组蛋白的免疫刺激能力，使得Eg95‑TM16 mRNA‑LNP可以同时发挥细粒棘球蚴和脑多头蚴的免疫保护作用，有望成为新的抗细粒棘球蚴和脑多头蚴的新型免疫预防手段。
Absstract of: CN121846128A
本发明属于生物医药技术领域，具体涉及一种巨噬细胞仿生囊泡纳米制剂及其制备方法和应用。本发明提供了一种巨噬细胞仿生囊泡纳米制剂，使用肿瘤靶向肽对巨噬细胞仿生囊泡进行修饰，并包裹靶向NSUN家族甲基转移酶siRNA。经肿瘤靶向肽修饰后的巨噬细胞仿生囊泡具有良好的胃癌细胞靶向性，包裹靶向NSUN家族甲基转移酶siRNA可抑制胃癌细胞NSUN表达水平、降低胃癌m5C异常修饰水平，达到增强PD‑1抗体治疗胃癌效果。实施例结果表明，本发明提供的巨噬细胞仿生囊泡纳米制剂作用于胃癌细胞，能够特异性靶向胃癌细胞，诱导胃癌细胞铁死亡，提高PD‑1抗体疗效，延长小鼠生存时间，改善肿瘤免疫微环境。
Absstract of: WO2024208280A1
The present invention relates to a polymer microsphere loaded with active metal particles, and a preparation method and application therefor, belonging to the technical field of tumor embolism treatment. The polymer microsphere loaded with active metal particles comprises a polymer microsphere skeleton and active metal particles distributed in the polymer microsphere skeleton. In the invention, the target microsphere is prepared mainly by using a reversed-phase microemulsion method. The polymer microsphere loaded with active metal particles is used for arterial tumor embolization, and can embolize a tumor blood vessel, block nutrient supply of the tumor part, slowly and continuously release hydroxide in situ to regulate the weakly acidic tumor microenvironment, release hydrogen to activate immune response, initiate hydrogen treatment, and amplify embolism treatment. The solution shows a better combined treatment effect compared with using only polymer microsphere embolism treatment.
Absstract of: WO2025017142A1
Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a stabilised prefusion RSV F protein immunogen linked to a scaffold based on lumazine synthase.
Absstract of: AU2009307677A1
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Absstract of: EP3842452A1
The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.
Absstract of: WO2021123332A1
The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.
Absstract of: CN121846313A
本发明公开了一种修饰可电离胺基的双介孔二氧化硅纳米颗粒及其制备方法和应用，其核心技术流程包括：首先通过嵌段共聚物与表面活性剂的双模板法合成介孔二氧化硅；然后将可电离胺基通过硅烷偶联剂接枝到介孔二氧化硅表面；最后利用静电吸附将RNA负载到修饰后的介孔二氧化硅上，最终实现肿瘤高效治疗。本发明还公开一种上述二氧化硅纳米颗粒在RNA递送中的应用，根据本发明方法制备的二氧化硅纳米颗粒有着高效的RNA负载效率以及细胞摄取效率。根据本发明制备的修饰可电离氨基团的双介孔二氧化硅纳米颗粒具有药物负载量大、细胞摄取率高、生物相容性高、合成简单、反应条件温和、便于裁剪等优点，具有良好的应用前景。
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: WO2018200943A1
Compounds are provided having one of the the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Absstract of: JP2026511197A
本発明は、少なくとも1つのゼオライトナノ結晶から成る、又は、少なくとも1つのゼオライトナノ結晶を含むナノ粒子を合成する方法であって、－アルミニウム供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第一の組成物／溶液１が調製され；－ケイ素供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第二の組成物／溶液２が調製され、ここで、前記組成物／溶液１及び２は、何らの有機構造化剤をも含まない；－前記２つの組成物／溶液１及び２が一緒に混合され；－前記混合物が結晶化され；かつ、－このようにして形成された前記ナノ粒子が分離されてよい方法に関する。本発明によれば、前記第一の組成物／溶液１及び前記第二の組成物／溶液２はいずれも、前記供給源及びリン酸緩衝生理食塩水から成る。本発明はまた、得られたナノ粒子のコロイド状懸濁液及び該ナノ粒子を含む医薬品組成物に関する。
Absstract of: CN120826370A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular of Na; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of Na, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing compositions/solutions 1 and 2 and placing the mixture under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating the formed nanoparticles. According to the invention, the first composition/solution 1 and the second composition/solution 2 each consist of said source and an alkaline phosphate buffer (PBS). The invention also relates to the nanoparticles thus obtained and to compositions containing these nanoparticles.
Absstract of: WO2024206076A1
The present disclosure pertains to biodegradable polymeric microspheres that comprise a biodegradable polymer and an immunotherapeutic agent selected from an inhibitor of poly ADP ribose polymerase enzyme (PARP inhibitor) and/or a Toll-like receptor (TLR) agonist wherein (a) 50% of a total amount of the immunotherapeutic agent in the biodegradable polymeric microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; (b) between 1 mg and 100 mg of immunotherapeutic agent per 1 g dry weight of microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; or (c) both (a) and (b). Other aspects of the present disclosure pertain to methods of using such microparticles and kits that contain such microparticles.
Absstract of: JP2026511099A
本明細書では、ＬＰＡ遺伝子におけるインビボ編集を達成することを対象とする遺伝子編集システム及び組成物が提供される。遺伝子編集によるアポ（ａ）産生の妨害及び血中リポタンパク質（ａ）［Ｌｐ（ａ）］濃度の低減による心血管疾患の治療又は予防が本明細書に開示される。ＬＰＡのコード配列における挿入及び／又は欠失（インデルバリアント）及び／又は非同義バリアントの導入を達成するように設計されたニッカーゼに基づく遺伝子編集システムが開示される。ニッカーゼに基づく遺伝子編集システムは一般に、１つ以上のニッカーゼと、複数のガイドオリゴヌクレオチド（例えば、ｇＲＮＡ）をコードする１つ以上のｍＲＮＡとを含み、それを必要とする哺乳動物対象に、潜在的に一回限りの治療として、（ＧａｌＮＡｃ標的化部分を有する、又は有さない）脂質ナノ粒子（ＬＮＰ）などの好適な送達システムを介して静脈内にインビボで送達され得るか、又は別の方法で投与され得る。遺伝子編集システム及び組成物の製造、使用、及び製剤化も開示される。
Absstract of: WO2024193827A1
The present disclosure relates generally to the field of stabilized compositions comprising particles dispersed in an aqueous phase, wherein the aqueous phase comprises a buffer system and has a pH of about 4.0-5.5 and wherein the particles contain (i) nucleic acid (such as DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA); and (ii) a cationic or cationically ionizable lipid, methods for preparing and storing such compositions, and the use of such compositions in therapy.
Absstract of: WO2024182676A2
The present disclosure provides antisense oligonucleotide compounds and compositions (e.g., pharmaceutical compositions) targeting NLRP3 and/or NLRP1 mRNA, and methods for treating diseases or conditions associated with NLRP3 and/or NLRP1 mRNA expression or NLRP3 and/or NLRP1 inflammasome activation. Exemplary conditions for which the compounds and compositions find use include inflammatory diseases such as neurodegenerative and autoimmune diseases, among others.
Absstract of: JP2026062827A
【課題】新規カチオン性脂質、治療剤の送達のための脂質ナノ粒子製剤の成分としての該化合物の使用、該化合物を含むナノ粒子、およびそれらの使用を提供する。【解決手段】下記の構造で示される化合物、またはその薬学的に許容される塩、互変異性体、または立体異性体が提供される。JPEG2026062827000031.jpg4868【選択図】なし
Absstract of: WO2021226108A1
Disclosed are pharmaceutical or cosmetic compositions comprising secretomes, for example secreted proteins from stem cells, and uses thereof. A composition that contains a secretome and an acceptable excipient may be free of a cell. The compositions are useful for inducing an immune response, treating an inflammatory response, treating a microbial infection, differentiating cells, wound healing, embryonic development, placental development, central nervous system development, or morphogenesis.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: WO2020146805A1
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, G1, G2, and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: US20260097112A1
0000 The present disclosure provides vaccine compositions comprising a plurality of distinct antigens. Also provided are nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens. The plurality of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mRNA/LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of inducing an immune response are also disclosed.
Absstract of: US20260096986A1
Drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the drug entrapped therein for at least about 3 hours.
Absstract of: US20260096990A1
0000 A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.
Absstract of: US20260096998A1
0000 The present disclosure provides complexes and methods of use. In some embodiments, a complex described herein is a complex comprising a cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer. In some embodiments, a complex comprises a linear cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer.
Absstract of: US20260098070A1
0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
Absstract of: US20260097103A1
0000 The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.
Absstract of: US20260097138A1
Metal based nanoparticles coated with a polymer functionalized with thiol groups and —NH groups are provided. The polymer can be thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic acid, or a protein such as albumin or gelatin, or a synthetic thiolated and aminated polymer such as α-thio-ω-amino polyethylene glycols. The groups are linked to a ligand of the integrin family receptors via a heterobifunctional crosslinker bearing functional groups able to bind to amino groups such as N-hydroxysuccinimidyl ester group (NHS ester), an isocyanate group (—NCO), an isothiocyanate group (—NCS), a Sulfo-N-hydroxysuccinimidyl ester group (sulfo-NHS ester), or a carboxylic acid group which is connected by activation with carbodiimide coupling agents; and/or a functional group able to bind thiol groups.
Absstract of: US20260097000A1
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Absstract of: US20260097133A1
0000 The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
Absstract of: US20260097130A1
The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.
Absstract of: US20260097095A1
0000 PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.
Absstract of: WO2026076250A1
The present disclosure relates to LNP formulations useful for uptake in the CNS or brain, for example, in some cases wherein the LNP is conjugated to an antigen binding fragment of an anti-transferrin receptor antibody. The present disclosure also relates to methods of delivering lipid nanoparticles (LNPs) systemically, for uptake in vivo in the central nervous system (CNS), such as to brain cells, and methods for assessment of the extent of uptake in CNS cells, such as brain cells. In some cases, methods allow for high throughput screening of multiple different LNPs in parallel.
Absstract of: WO2026074515A1
The present invention relates to nanoparticles formed by a hollow polymeric wall, capable of transporting drugs and active substances, or contrast media, across cellular membranes and releasing them at sites of interest. The nanoparticles are formed by self-assembly of poly(isobutene-alt-maleic anhydride) functionalised with an aminosaccharide.
Absstract of: WO2026075526A1
The present invention relates to a composition for treating psoriasis diseases using nano-graphene oxide. It was confirmed that the nano-graphene oxide of the present invention regulates inflammatory immune cell subtypes and tissue-resident memory cells, which are psoriasis-pathogenic immune cells. In addition, in an acute psoriasis animal model, it was confirmed that skin thickness, scaling, and erythema were reduced, and the thickness of the epidermal layer was decreased. Furthermore, it was confirmed that immune cells are regulated by reducing psoriasis-pathogenic immune cells and increasing immunoregulatory cells in splenocytes. Moreover, it was confirmed that mitochondrial functions are regulated by increasing mitochondrial ROS and oxygen consumption rates in psoriasis-pathogenic immune cells.
Absstract of: WO2026075516A1
The present invention relates to a polymer nanocomposite for brain-targeted drug delivery and a pharmaceutical composition comprising same. The polymer nanocomposite of the present invention has a structure in which (a) a cyclodextrin derivative bonded to a piperazine derivative, which is a brain-targeting ligand, and (b) a polymer chain bonded to a hydrophobic compound, which is a guest molecule, are self-assembled through host-guest interaction. The nanocomposite is loaded with a therapeutic drug and can efficiently penetrate the blood-brain barrier and deliver the drug to brain tissue through intranasal administration, which is a non-invasive route.
Absstract of: WO2026074471A1
Provide herein are methods of treating non-small cell lung cancer (NSCLC) in an individual in need thereof by administering a combination of a nanoparticle composition comprising HfO2, radiation therapy, chemotherapy, and a PD-L1 antibody to the individual. Also provided are methods of selecting an individual for treatment of NSCLC according to the methods provided herein.
Absstract of: WO2026076406A1
Compositions and methods for treating chlorine gas-induced pulmonary injury are disclosed. The described approach targets calcium/calmodulin-dependent protein kinase II (CaMKII), an enzyme activated in lung cells upon chlorine exposure, which contributes to oxidative stress and inflammation. The compositions include one or more CaMKII inhibitors, such as CaMKIIN peptides, encapsulated in liposomes and/or nanoparticles designed for pulmonary delivery. The liposomes can be conjugated with mitochondrial targeting moieties, such as triphenyl phosphonium bromide (TPP), to enhance delivery to mitochondria, where CaMKII activation occurs. The method involves administering the composition via inhalation or other routes to mitigate lung damage, reduce oxidative stress, and improve pulmonary function. This approach provides a targeted and effective solution for managing chlorine¬ induced respiratory distress, addressing limitations of current therapies.
Absstract of: US20260098014A1
Disclosed are lipidoid compounds having the structure of formula (I):or a salt thereof, wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Absstract of: US20260097223A1
A system is provided for use with a subject suffering from cancer that includes one or more primary or metastatic solid tumors. The system includes nanoparticles including a magnetic metallic core and a phase-change material (PCM) that surrounds the magnetic metallic core and is configured to absorb latent heat of fusion by undergoing a phase change that occurs at a phase-change temperature of 42-80 degrees C. A radiofrequency (RF) transmitter is configured to transmit energy, in a pulse train alternating between high power and low power at a pulse frequency of 1 Hz-5 Hz, to at least a portion of the subject's body, such so that the nanoparticles are heated to the phase-change temperature of the PCM, and store energy from the pulse train in the PCM as latent heat of fusion. Other embodiments are also described.
Absstract of: WO2026075245A1
The present invention relates to: a modified mRNA comprising an open reading frame (ORF) encoding a protein, a poly A region on the 3'-side of the ORF, and biotin or an analog thereof bound to the 3'-end of the poly A region; and a pharmaceutical composition comprising the modified mRNA.
Absstract of: WO2026073350A1
A method for reprogramming native CD4+ T-cells is provided. The method comprises incubating the CD4+ T-cells with a Class 1 HDAC inhibitor for a period of time sufficient to increase cytotoxicity of the CD4+ T-cells in comparison to the cytotoxicity of native CD4+ T-cells. The method may be utilized to prepare cytotoxic tumor infiltrating CD4+ T-cells for use to treat cancer, including MHC-I deficient cancers.
Absstract of: WO2026074585A1
The present invention relates to a method for coating a medical device with nano- encapsulated drug using membrane technology. The said medical device is for interventional procedures. The invention discloses the design, formulation, technology features and potential clinical applications, emphasizing its role in improving outcomes in interventional procedures.
Absstract of: WO2026076254A1
The disclosure relates to methods of using block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to methods of using polymer nanoparticles for delivering nucleic acids for treating NF1.
Absstract of: WO2026076268A1
The present invention relates to a system and method for generating and dispersing a mixture of nanoparticles and ions for neutralization of airborne pathogens in enclosed environments. A nebulizer introduces a salt precursor into a flame ionization stage, which produces a mixture of ions and nanoparticles at concentrations of at least 1.0 X 10^12 particles per cubic centimeter of air. The nanoparticles have an average size of less than 10 nanometers, and at approximately equal proportions with the ions. The systems and methods of the present invention reduce the pathogen viability by neutralization, inactivation, and agglomeration, and operate substantially free of ozone and, in alternate embodiments, include a two-duct alternating filtration arrangement for efficiency. Methods of testing include introducing pathogen surrogates into a chamber, generating the mixture of nanoparticles and ions by flame ionization, dispersing the mixture, and analyzing samples using aerosol and microbiological characterization techniques.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: US20260097001A1
0000 A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
Absstract of: US20260096988A1
0000 The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents
Absstract of: US20260096997A1
0000 A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA, comprising silicon nanoparticles, at least one amino acid, and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.
Absstract of: AU2026202230A1
Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided. ar a r
Absstract of: AU2026202084A1
AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) 5 vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor 10 receptor operably linked to a signal peptide. ar - a r
Nº publicación: AU2026202066A1 09/04/2026
Applicant:
ROCK BIOMEDICAL INC
Absstract of: AU2026202066A1
Abstract The present disclosure relates to lipid nanoparticles (LNP) and kits for making these, for the delivery of therapeutic molecules. Specifically, these LNPs comprise a plural of lipid components, comprising a lipid tail to be incorporated into a bilayer membrane, and a targeting moiety to provide selective delivery of the nanoparticle to a desired tissue. WO 2024/215614 PCT/US2024/023590 a §e « <0 ^iiis25 e$ *—£• s 5n sx s$?■' ’''NW.W.WA !i tft 4 . .'.W -t- ■MMMMMNM ! 5> 2«5K«K2 ijg fi, Jt* BSSSSSS.vvvvvvvvv.\j R~ SJSNWU wTttw Is »ja«^vvw^wvvv\vvw.v.v.v' **w»^^Vi>>>>>>>>mV»\ »yv 8?/* «w<5t\\\\\\v-: C5:::: , ...WKTOCWCWSSK5 S < > 5$8 'w*XNN'\'\'\'vXJ •-v--------w.v.vvr ^ y Jj» JAWXWAAft- I«S35 .VO.Vv\v!!vv!vv vWJJK s sssSt!
BOPI
Electronic site
